JP2022535276A5 - - Google Patents

Info

Publication number
JP2022535276A5
JP2022535276A5 JP2021572333A JP2021572333A JP2022535276A5 JP 2022535276 A5 JP2022535276 A5 JP 2022535276A5 JP 2021572333 A JP2021572333 A JP 2021572333A JP 2021572333 A JP2021572333 A JP 2021572333A JP 2022535276 A5 JP2022535276 A5 JP 2022535276A5
Authority
JP
Japan
Prior art keywords
antibody
represented
seq
complex
complex according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021572333A
Other languages
English (en)
Japanese (ja)
Other versions
JP7260677B2 (ja
JP2022535276A (ja
Filing date
Publication date
Priority claimed from GBGB1908128.0A external-priority patent/GB201908128D0/en
Application filed filed Critical
Publication of JP2022535276A publication Critical patent/JP2022535276A/ja
Publication of JP2022535276A5 publication Critical patent/JP2022535276A5/ja
Application granted granted Critical
Publication of JP7260677B2 publication Critical patent/JP7260677B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021572333A 2019-06-07 2020-06-04 ピロロベンゾジアゼピン-抗体複合体 Active JP7260677B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1908128.0 2019-06-07
GBGB1908128.0A GB201908128D0 (en) 2019-06-07 2019-06-07 Pyrrolobenzodiazepine-antibody conjugates
PCT/EP2020/065506 WO2020245283A1 (en) 2019-06-07 2020-06-04 Pyrrolobenzodiazepine-antibody conjugates

Publications (3)

Publication Number Publication Date
JP2022535276A JP2022535276A (ja) 2022-08-05
JP2022535276A5 true JP2022535276A5 (cg-RX-API-DMAC7.html) 2022-11-16
JP7260677B2 JP7260677B2 (ja) 2023-04-18

Family

ID=67386092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572333A Active JP7260677B2 (ja) 2019-06-07 2020-06-04 ピロロベンゾジアゼピン-抗体複合体

Country Status (16)

Country Link
US (1) US11484606B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980077A1 (cg-RX-API-DMAC7.html)
JP (1) JP7260677B2 (cg-RX-API-DMAC7.html)
KR (1) KR102495245B1 (cg-RX-API-DMAC7.html)
CN (1) CN114375204B (cg-RX-API-DMAC7.html)
AR (1) AR119086A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020287248A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024646A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142448A1 (cg-RX-API-DMAC7.html)
GB (1) GB201908128D0 (cg-RX-API-DMAC7.html)
IL (1) IL288681A (cg-RX-API-DMAC7.html)
MX (1) MX2021015101A (cg-RX-API-DMAC7.html)
PH (1) PH12021552937A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112821XA (cg-RX-API-DMAC7.html)
WO (1) WO2020245283A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109660B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180487A (ja) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd 抗生物質dc−81およびその製造法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6218519B1 (en) 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
WO1999061061A1 (fr) 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Composites medicamenteux
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6268488B1 (en) 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
US20040052793A1 (en) 2001-02-22 2004-03-18 Carter Paul J. Caspase activivated prodrugs therapy
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
AU2005214988A1 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
CA2596833C (en) 2005-02-03 2016-04-12 Antitope Limited Human antibodies and proteins
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
JP5702290B2 (ja) 2008-10-15 2015-04-15 ジンマー ゲーエムベーハー 髄内釘
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
CN103068405A (zh) 2010-04-15 2013-04-24 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
WO2011130615A2 (en) 2010-04-15 2011-10-20 Dr. Reddy's Laboratories Ltd. Preparation of lacosamide
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
PT2906252T (pt) 2012-10-12 2017-09-19 Medimmune Ltd Conjugados de anticorpo anti-her2 de pirrolobenzodiazepina
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
WO2014057118A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
US20160106861A1 (en) 2013-04-26 2016-04-21 Spirogen Sarl Axl antibody-drug conjugate and its use for the treatment of cancer
WO2015052533A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506405D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506399D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506407D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506388D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W Site-specific antibody-drug conjugates
GB201506409D0 (en) 2015-04-15 2015-05-27 Williams David G And Berkel Patricius H C Van And Howard Philip W Humanized anti-axl antibodies and their conjugates
GB201506394D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201507827D0 (en) 2015-05-07 2015-06-17 Adc Therapeutics Sarl Diagnostic test
GB201513607D0 (en) 2015-07-31 2015-09-16 Feingold Jay M Pyrrolobenzodiazepine-antibody conjugates
GB201602363D0 (en) 2016-02-10 2016-03-23 Adc Therapeutics Sa And Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) * 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018146199A1 (en) * 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2018193103A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-psma antibody-drug conjugate
EP3612839A1 (en) 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy
CA3057744A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-cd25 antibody-drug conjugate
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
KR20200028950A (ko) 2017-06-14 2020-03-17 에이디씨 테라퓨틱스 에스에이 항-cd25 adc의 투여를 위한 투약량 체제
CA3098103A1 (en) * 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20220347309A1 (en) * 2018-12-19 2022-11-03 Adc Therapeutics Sa Pyrrolobenzodiazepine resistance

Similar Documents

Publication Publication Date Title
JP2023522229A5 (cg-RX-API-DMAC7.html)
JP2022101693A5 (cg-RX-API-DMAC7.html)
JP2024150445A5 (cg-RX-API-DMAC7.html)
JP2021501162A5 (cg-RX-API-DMAC7.html)
JP2015534579A5 (cg-RX-API-DMAC7.html)
RU2019138337A (ru) Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии
JP2021516973A5 (cg-RX-API-DMAC7.html)
JP2021533726A5 (cg-RX-API-DMAC7.html)
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2017186337A5 (cg-RX-API-DMAC7.html)
JP2012522513A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2021527640A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2020509027A5 (cg-RX-API-DMAC7.html)
JP2017514461A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2015533781A5 (cg-RX-API-DMAC7.html)
JP2025183307A5 (cg-RX-API-DMAC7.html)
JP2024520666A5 (cg-RX-API-DMAC7.html)
JP2020500834A5 (cg-RX-API-DMAC7.html)
JP2020522280A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2023516195A (ja) C19 c38二特異性抗体
JP2020515577A5 (cg-RX-API-DMAC7.html)